Protocol #28821: A Phase III, randomized, double-blind, placebo-controlled, multi-center clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS
|Effective start/end date||12/1/08 → 11/30/12|
- EMD Serono, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.